FDA OKs Janssen's once-daily T2D treatment INVOKAMET XR

• The FDA approves Janssen Pharmaceuticals' (NYSE:JNJ) INVOKAMET XR (canagliflozin/metformin hydrochloride extended release) as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes (T2D). The once-daily pill combines INVOKANA (canagliflozin) with an extended-release formulation of metformin.
• Previously: Janssen submits NDA for extended release formulation of INVOKAMET for type 2 diabetics (Nov. 20, 2015)